SCHEMBL4335941

SCHEMBL4335941

COc1cc2[nH]nc(-c3cc4ccccc4s3)c2cc1C(=O)NCc1cccs1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
TP53 P04637 3/20 0.49
HPGD P15428 6/20 0.44
HSD17B10 Q99714 5/20 0.44
ALDH1A1 P00352 5/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
RAB9A P51151 3/20 0.44
POLB P06746 2/20 0.44
MAPK10 P53779 2/20 0.44
NPC1 O15118 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
KDM4E B2RXH2 3/20 0.44
GAA P10253 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4340978 0.86 ALDH1A1 (0.46) MAPTSMN1; SMN2HPGDHSD17B10ALDH1A1
SCHEMBL4341021 0.85 MAPT (0.49) MAPTSMN1; SMN2TP53HPGDHSD17B10
SCHEMBL4334979 0.84 MAPT (0.44) MAPTSMN1; SMN2TP53HPGDHSD17B10
SCHEMBL2864411 0.83 MAPK10 (0.46) MAPK10KDRMAPK1
SCHEMBL2862326 0.81 KDM4E (0.46) HPGDHSD17B10ALDH1A1MAPK10KDM4E
SCHEMBL2870547 0.80 RAB9A (0.48) SMN1; SMN2ALDH1A1RAB9AMAPK10KDR
SCHEMBL4338881 0.80 KDM4E (0.53) MAPTSMN1; SMN2HPGDHSD17B10ALDH1A1
SCHEMBL4336833 0.79 MAPK10 (0.40) RAB9AMAPK10NPC1MAPK1
SCHEMBL4329239 0.79 MAPK1 (0.45) MAPK10MAPK1
SCHEMBL2864589 0.78 HPGD (0.44) MAPTSMN1; SMN2TP53HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 MAPT 2644/4885SMN1; SMN2 4812/4885TP53 1560/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 MAPT 2644/4885SMN1; SMN2 4812/4885TP53 1560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.